Lauren Riley

Utilize Tune Therapeutics Epigenetic Editing platform to modulate gene expression in primary human cells with the goal of developing therapeutic interventions Developing Immunoassays to asses functionality of primary T cells Developing multicolor flow cytometry panels (surface & intracellular) for evaluating phenotypic changes Produce samples and materials for methyl-sequencing and RNAseq to evaluate epigenetic editing Work with cross-team functionality to rapidly produce new epigenetic editing machinery for new targets Train incoming technicians and Scientists for Flow Cytometry and FACS

Utilized Tune’s Tempo platform to execute epigenetic modifications to CAR-T cells, Hepatitis B infected primary human hepatocytes, and primary T cells ●Evaluated epigenetic modifications effects on both CAR-T cells and T cells via proliferation, killing, cytokine production assays by Flow & MSD, Treg suppression assays and validated epigenetic changes via qPCR ●Perform HBV infections on primary human or cell line hepatocytes. Then further transfected these cells with epigenetic modifiers (by lipofection or LNP) as research treatment. ●Produced methyl-seq libraries to evaluate the methylation landscape of virally transfected cells ●Developed protocol for the isolation of viral DNA from supernatants for the evaluation of HBV infection levels ● Ran IP-RP HPLC on mRNA and LNP drug substances to develop protocols for purity evaluations

Dept. of Immunology, Dept. of Hematologic Malignancies and Cellular Therapies Dr. Stephanie Sarantopoulos's Lab Duke University, Durham, NC ● Designed and investigated an innovative dissertation proposal researching the role of EBI2 (GPR183) in modulating the activation response of post-transplant B-cells in the spleen of mice and humans ● Provided weekly project update presentations including a review of the effects of bone marrow transplant ●Built and maintained a mouse colony of human EBI2-overexpressing transgenic mice from viably frozen sperm ● Evaluated the possible modulation of B cell receptor (BCR) activation by EBI2 tonic and active signaling via phosphoflow cytometry, proliferation assays, IHC fluorescent microscopy, and migration assays ●Maintained mice after the trauma of bone marrow transplants until their humane endpoints to evaluate the development of chronic graft versus host disease like pathology

Maus Lab, Cellular Immunotherapy Program, Harvard University & Massachusetts General Hospital Lentiviral transduction of T-cells to produce CAR T-cells Produce growth curves, cytotoxicity assays, and cytokine production evaluations of CAR T cells Isolate and freeze down primary human and mouse PBMCs, bulk T cells, CD4+ T cell subsets, and NK cells Using flow cytometry to assess transduction efficiency of CAR T cells Isolate lymphocytes from mouse blood and tissue; identify CAR T cell and tumor cell populations by flow cytometry for analysis of persistence of these populations during in vivo experiments Maintenance of HEK cell population for lentivirus production; Lentivirus production Cloning elements into and out of our CAR T cell backbone to produce and evaluate differential designs Manage laboratory equipment repairs, supply orders, and purchase order requests for lab

Worked with a team to analyze RNAi screens of genes related to insulin signaling in response to a high-glucose diet in Daf-1 mutant Caenorhabditis elegans Independently designed and ran experiments on carbohydrate catabolism Attended weekly lab meetings and presented research papers and current data to PI and other lab members Presented Research at The Allied Genetics Conference in Orlando, FL